Established in 1999, Chengda Pharmaceutical Co., Ltd. is a high-tech enterprise whose main business is R&D, production and sales of pharmaceutical intermediates, chemical raw materials, food and feed additives. It was listed on the Shenzhen Stock Exchange in 2022. The company is committed to providing CDMO services for multinational pharmaceutical companies and pharmaceutical R&D institutions such as process development and optimization, quality research and customized production of key pharmaceutical intermediates and APIs during drug clinical trials and commercialization stages. Terminal drugs cover various treatment fields such as antitumor, antiviral, neurological, and diabetes. The company's main business covers providing CDMO R&D and production services for key pharmaceutical intermediates and pharmaceutical R&D institutions, as well as R&D, production and sales of L-carnitine series products and generic drug APIs for multinational pharmaceutical companies and pharmaceutical R&D institutions. The company's products include food additives, feed additives, and APIs. Corporate honors: In 2023, it won the second batch of benchmark projects in Zhejiang Province - pollution reduction and carbon reduction project, Jiaxing City Waste-free Plant, Jiaxing Fire Service “Five Advance” pilot units, Jiaxing Key Enterprise Compliance Construction Pilot Unit, 17th Jiashan County Mayor Quality Award, High-tech Enterprise Certificate, National Key New Product (L-carnitine) certificate, etc.
No Data
No Data